1. ZIKA Virus Neutralizing Antibody Kinetics in Antenatally Exposed Infants
- Author
-
Zilton Vasconcelos, Claudia Raja Gabaglia, Luana Damasceno, Patrícia Brasil, Myrna C. Bonaldo, Thomas Jaenisch, James D. Cherry, Liege Maria Abreu de Carvalho, Boris Pastorino, Andrea Zin, Maria Elisabeth Lopes Moreira, Otávio de Melo Espíndola, Denise Cotrim da Cunha, Marcos Vinicius da Silva Pone, Karin Nielsen-Saines, Raquel de Vasconcellos Carvalhaes de Oliveira, Sheila Moura Pone, Xavier de Lamballerie, and Ieda Pereira Ribeiro
- Subjects
Male ,Pathogenesis and Host Response ,0301 basic medicine ,medicine.medical_specialty ,Antibodies, Viral ,Polymerase Chain Reaction ,Gastroenterology ,03 medical and health sciences ,0302 clinical medicine ,Pregnancy ,Internal medicine ,Parenchyma ,medicine ,Humans ,Immunology and Allergy ,030212 general & internal medicine ,Pregnancy Complications, Infectious ,Neutralizing antibody ,Subclinical infection ,biology ,Zika Virus Infection ,business.industry ,Infant, Newborn ,Infant ,Zika Virus ,Hypervascularity ,Odds ratio ,Antibodies, Neutralizing ,Infectious Disease Transmission, Vertical ,3. Good health ,Kinetics ,030104 developmental biology ,Infectious Diseases ,Immunoglobulin M ,biology.protein ,Biomarker (medicine) ,Female ,business ,Biomarkers ,Kappa - Abstract
Background Zika virus (ZIKV) is associated with severe congenital abnormalities and laboratory diagnosis of antenatal infection is difficult. Here we evaluated ZIKV neutralizing antibody (nAb) kinetics in infants born to mothers with PCR-confirmed ZIKV infection during pregnancy. Methods Neonates (n = 98) had serum specimens tested repeatedly for ZIKV nAb over the first 2 years of life using virus neutralization test (VNT). ZIKV neonatal infection was confirmed by RT-PCR in blood or urine and/or presence of ZIKV IgM antibodies, and results were correlated with infant clinical features. Results Postnatal laboratory evidence of ZIKV vertical transmission was obtained for 60.2% of children, while 32.7% exhibited clinical abnormalities. Congenital abnormalities were found in 37.3% of children with confirmed ZIKV infection and 31.0% of children without confirmed infection (P = .734). All but 1 child displayed a physiologic decline in ZIKV nAb, reflecting maternal antibody decay, despite an early ZIKV-IgM response in one-third of infants. Conclusions Infants with antenatal ZIKV exposure do not develop ZIKV nAb despite an early IgM response. Therefore, ZIKV VNT in children is not useful for diagnosis of congenital infection. In light of these findings, it remains to be determined if children infected in utero are potentially susceptible to reinfection.
- Published
- 2021
- Full Text
- View/download PDF